Search Results - "LAWITZ, Eric J"

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials by Anstee, Quentin M., Lawitz, Eric J., Alkhouri, Naim, Wong, Vincent Wai‐Sun, Romero‐Gomez, Manuel, Okanoue, Takeshi, Trauner, Michael, Kersey, Kathryn, Li, Georgia, Han, Ling, Jia, Catherine, Wang, Lulu, Chen, Guang, Subramanian, G. Mani, Myers, Robert P., Djedjos, C. Stephen, Kohli, Anita, Bzowej, Natalie, Younes, Ziad, Sarin, Shiv, Shiffman, Mitchell L., Harrison, Stephen A., Afdhal, Nezam H., Goodman, Zachary, Younossi, Zobair M.

“…Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced fibrosis caused by nonalcoholic steatohepatitis (NASH). We…”
Get full text

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients by Pockros, Paul J., Fuchs, Michael, Freilich, Bradley, Schiff, Eugene, Kohli, Anita, Lawitz, Eric J., Hellstern, Paul A., Owens‐Grillo, Janet, Van Biene, Courtney, Shringarpure, Reshma, MacConell, Leigh, Shapiro, David, Cohen, David E.

“…Background & Aims Nonalcoholic steatohepatitis (NASH) is a chronic and severe form of nonalcoholic fatty liver disease that can progress to cirrhosis and…”
Get full text

Treatment of HCV Infection by Targeting MicroRNA by Janssen, Harry L.A, Reesink, Hendrik W, Lawitz, Eric J, Zeuzem, Stefan, Rodriguez-Torres, Maribel, Patel, Keyur, van der Meer, Adriaan J, Patick, Amy K, Chen, Alice, Zhou, Yi, Persson, Robert, King, Barney D, Kauppinen, Sakari, Levin, Arthur A, Hodges, Michael R

“…In this phase 2 trial, an antisense oligonucleotide was tested in the treatment of chronic hepatitis C virus infection. The oligonucleotide was designed to…”
Get full text

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein by Lawitz, Eric J, Dvory-Sobol, Hadas, Doehle, Brian P, Worth, Angela S, McNally, John, Brainard, Diana M, Link, John O, Miller, Michael D, Mo, Hongmei

“…Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to…”
Get full text

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial by Kwo, Paul Y, Dr, Lawitz, Eric J, MD, McCone, Jonathan, MD, Schiff, Eugene R, Prof, Vierling, John M, Prof, Pound, David, MD, Davis, Mitchell N, DO, Galati, Joseph S, MD, Gordon, Stuart C, MD, Ravendhran, Natarajan, MD, Rossaro, Lorenzo, Prof, Anderson, Frank H, MD, Jacobson, Ira M, Prof, Rubin, Raymond, MD, Koury, Kenneth, PhD, Pedicone, Lisa D, PhD, Brass, Clifford A, MD, Chaudhri, Eirum, MD, Albrecht, Janice K, PhD

“…Summary Background Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients with genotype 1 chronic hepatitis…”
Get full text

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients by Lawitz, Eric J., Li, Kelvin W., Nyangau, Edna, Field, Tyler John, Chuang, Jen-Chieh, Billin, Andrew, Wang, Lulu, Wang, Ya, Huss, Ryan S., Chung, Chuhan, Subramanian, G. Mani, Myers, Robert P., Hellerstein, Marc K.

“…De novo lipogenesis (DNL) converts carbon substrates to lipids. Increased hepatic DNL could contribute to pathogenic liver triglyceride accumulation in…”
Get full text

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment by Khatri, Amit, Menon, Rajeev M, Marbury, Thomas C, Lawitz, Eric J, Podsadecki, Thomas J, Mullally, Victoria M, Ding, Bifeng, Awni, Walid M, Bernstein, Barry M, Dutta, Sandeep

“…Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of…”
Get full text

Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment by Qosa, Hisham, de Oliveira, Claudia H. M. C., Cizza, Giovanni, Lawitz, Eric J., Colletti, Nicholas, Wetherington, Jeffrey, Charles, Edgar D., Tirucherai, Giridhar S.

“…BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific…”
Get full text

Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function by Yin, Wei, Mitra, Pranab, Copalu, Veronique, Marbury, Thomas C., Rondon, Juan Carlos, Lawitz, Eric J., Lloyd, Valerie, Baratta, Mike, Asgharnejad, Mahnaz, Hui, Tom, Khan, Yasir

“…This phase 1, open‐label, three‐arm study (NCT05098054) compared the pharmacokinetics and safety of soticlestat (TAK‐935) in participants with hepatic…”
Get full text

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes by Younossi, Zobair M, Wong, Vincent Wai‐Sun, Anstee, Quentin M., Romero‐Gomez, Manuel, Trauner, Michael H., Harrison, Stephen A., Lawitz, Eric J., Okanoue, Takeshi, Camargo, Marianne, Kersey, Kathryn, Myers, Robert P., Goodman, Zachary, Stepanova, Maria

“…Fatigue and pruritus are common in patients with chronic liver diseases of all etiologies, but clinical awareness is mostly restricted to those with…”
Get full text

The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors by Membreno, Fernando E., MD, MSc, Lawitz, Eric J., MD, CPI

“…This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase…”
Get full text

Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients by DVORY-SOBOL, Hadas, WONG, Kelly A, KU, Karin S, BAE, Andrew, LAWITZ, Eric J, PANG, Phillip S, HARRIS, Jeanette, MILLER, Michael D, HONGMEI MO

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial by Sanyal, Arun, Charles, Edgar D, Neuschwander-Tetri, Brent A, Loomba, Rohit, Harrison, Stephen A, Abdelmalek, Manal F, Lawitz, Eric J, Halegoua-DeMarzio, Dina, Kundu, Sudeep, Noviello, Stephanie, Luo, Yi, Christian, Rose

“…Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver…”
Get full text

Cyclophilin Inhibitors for Hepatitis C Therapy by Membreno, Fernando E., MD, MSc, Espinales, Jennifer C, Lawitz, Eric J., MD, AGAF, CPI

“…This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that…”
Get full text

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease by Loomba, Rohit, Kayali, Zeid, Noureddin, Mazen, Ruane, Peter, Lawitz, Eric J., Bennett, Michael, Wang, Lulu, Harting, Eliza, Tarrant, Jacqueline M., McColgan, Bryan J., Chung, Chuhan, Ray, Adrian S., Subramanian, G. Mani, Myers, Robert P., Middleton, Michael S., Lai, Michelle, Charlton, Michael, Harrison, Stephen A.

“…De novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step…”
Get full text

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection by Ng, Teresa I, Pilot-Matias, Tami, Tripathi, Rakesh, Schnell, Gretja, Krishnan, Preethi, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Lu, Liangjun, Asatryan, Armen, Campbell, Andrew, Yao, Betty, Lovell, Sandra, Mensa, Federico, Lawitz, Eric J, Kort, Jens, Collins, Christine

“…Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals…”
Get full text

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial by Patel, Keyur, Harrison, Stephen A., Elkhashab, Magdy, Trotter, James F., Herring, Robert, Rojter, Sergio E., Kayali, Zeid, Wong, Vincent Wai‐Sun, Greenbloom, Susan, Jayakumar, Saumya, Shiffman, Mitchell L., Freilich, Bradley, Lawitz, Eric J., Gane, Edward J., Harting, Eliza, Xu, Jun, Billin, Andrew N., Chung, Chuhan, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Middleton, Michael S., Rinella, Mary, Noureddin, Mazen

“…Background and Aims We evaluated the safety and efficacy of cilofexor (formerly GS‐9674), a small‐molecule nonsteroidal agonist of farnesoid X receptor, in…”
Get full text

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis by Harrison, Stephen A., Abdelmalek, Manal F., Caldwell, Stephen, Shiffman, Mitchell L., Diehl, Anna Mae, Ghalib, Reem, Lawitz, Eric J., Rockey, Don C., Schall, Raul Aguilar, Jia, Catherine, McColgan, Bryan J., McHutchison, John G., Subramanian, G. Mani, Myers, Robert P., Younossi, Zobair, Ratziu, Vlad, Muir, Andrew J., Afdhal, Nezam H., Goodman, Zachary, Bosch, Jaime, Sanyal, Arun J.

“…Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal…”
Get full text

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis by Loomba, Rohit, Hartman, Mark L., Lawitz, Eric J., Vuppalanchi, Raj, Boursier, Jérôme, Bugianesi, Elisabetta, Yoneda, Masato, Behling, Cynthia, Cummings, Oscar W., Tang, Yuanyuan, Brouwers, Bram, Robins, Deborah A., Nikooie, Amir, Bunck, Mathijs C., Haupt, Axel, Sanyal, Arun J.

“…In this phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than…”
Get full text

Differences in treatment outcome for hepatitis C among ethnic groups by Hepburn, Matthew J, Hepburn, Lisa M, Cantu, Norma S, Lapeer, Maria G, Lawitz, Eric J

“…Studies of interferon-based therapies for hepatitis C virus (HCV)-infected patients have documented variable response rates according to ethnicity. However,…”
Get more information